All Immuno Content

Bringing you the latest research in immuno-oncology, autoimmunity, therapeutic modalities and more, through a range of Speaker Interviews, Industry Insights, and Expert Opinions.

Discussion Group Report
Dr. Vibha Jawa, Executive Director, Nonclinical Disposition and Bioanalysis at BMS
Edited by Tom Cohen |
02 August 2022
Translational & Preclinical Development
Commentary
Axel Ducret, a Roche Senior Principal Scientist, takes us through his work on one of the most important cellular mechanisms in immunotherapy.
01 July 2022
Translational & Preclinical Development
Discussion Group Report
CAR T, the rockstar therapy of immuno-oncology, finds its next big challenge in translating research for use in solid tumours.
Edited by Tom Cohen |
23 June 2022
Translational & Preclinical Development
Commentary
Single-cell, real-time analysis of oncolytic viruses’ efficacy, and replication in living cancer cells.
14 June 2022
Translational & Preclinical Development
Discussion Group Report
Ian A Wilson of ImaginAb delivers the presentation ‘The Value of In Vivo Imaging on the Clinical Development of IO Drugs’ at Oxford Global’s discussion group.
Edited by Tom Cohen |
14 April 2022
Translational & Preclinical Development
Commentary
Oxford Global’s Immuno Week showcased new ways of reprogramming the immune system to treat malignancy with TCR-T.
Edited by Tom Cohen |
08 April 2022
Translational & Preclinical Development
Written Q&A
An interview with Rajika Perera, Chief Executive Officer, Poseidon Laboratory
01 March 2022
Translational & Preclinical Development
Commentary
Improving preclinical modelling to translate drugs to the clinic is one of the key priorities in immunotherapy and immuno-oncology today. We sat down with senior representatives from GemPharmatech and MiNA Therapeutics to find out how best to develop the next generation of preclinical modelling.
Edited by Tia Byer |
15 December 2021
Translational & Preclinical Development
Whitepaper
The tumor microenvironment (TME) supports the development of pro-tumoral macrophages.
13 October 2021
Translational & Preclinical Development
Whitepaper
T cells can develop an exhausted phenotype as a result of prolonged antigen stimulation.
13 October 2021
Translational & Preclinical Development

Search by Keyword

Filter by Subject Area

Filter by Content Type

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.

Member Community Login